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Background: Imatinib, a tyrosine kinase inhibitor, has been proposed as a potential antifibrotic agent 
for fibroproliferative diseases, including bronchiolitis obliterans (BO). However, the underlying 
antifibrotic mechanisms of the agent remain unclear. We evaluated whether bone marrow-derived 
progenitor cells, fibrocytes, might be a target of imatinib in the attenuation of BO. 
Methods: We used a murine BO model induced by heterotopic tracheal transplantation, and assessed 
the origin of fibroblasts by using GFP-bone marrow (BM) chimeric mice. We also evaluated the effects 
of imatinib on luminal obstruction and fibrocyte accumulation. Additionally, the effects of imatinib on 
fibrocyte migration and differentiation were assessed by culturing fibrocytes in vitro.  
Results: In the murine BO model, tracheal allografts showed epithelial injury and developed complete 
luminal occlusion 28 days after transplantation. Most of the mesenchymal cells that had accumulated 
in the tracheal allograft were derived from BM cells. Imatinib treatment ameliorated the airway luminal 
occlusion and significantly reduced the number of fibrocytes in the allografts. In vitro studies showed 
that imatinib inhibited migration of cultured blood fibrocytes via the PDGF/PDGFR axis. Additionally, 
imatinib inhibited differentiation of fibrocytes via suppression of c-Abl activity that was essential for 
the differentiation of monocytes to fibrocytes. 
Conclusions: Imatinib prevents airway luminal obstruction by inhibiting the migration and 





Bronchiolitis obliterans (BO) is a fibroproliferative disorder resulting in terminal small airway 
occlusion that leads to an irreversible decline in lung function (1). BO occurs in more than 50% of lung 
transplant recipients within 5 years of lung transplantation, and it remains the predominant cause of 
morbidity and mortality following lung transplantation (2). BO responds poorly to corticosteroids or 
immunosuppressants. Lung transplant physicians and respirologists need to elucidate its pathogenesis 
and identify useful biomarkers for the diagnosis and severity of BO as well as effective interventions to 
prevent and treat BO.  
Imatinib is a tyrosine kinase inhibitor of Bcr-Abl, c-Abl, c-Kit, and PDGFR (3). Recent preclinical 
and clinical studies have suggested that imatinib is effective for the treatment of fibroproliferative 
disorders such as pulmonary fibrosis, lupus nephritis and pulmonary hypertension (4-8). We previously 
reported two cases of BO after allogeneic hematopoietic stem cell transplantation that were successfully 
treated with imatinib (9). In the two cases, imatinib treatment stabilized the patients’ pulmonary function 
and prolonged their survival time. Several studies have also described the efficacy of imatinib in the 
treatment of BO in patients with chronic graft-versus-host disease (10-12). In the rat BO model of 
heterotopic tracheal transplantation (HTT), imatinib inhibited the tracheal luminal occlusion 30 days 
after transplantation compared with vehicle-treated allografts (13, 14). Taken together, these data 
suggest that imatinib can be a useful agent for treating BO. 
The precise mechanisms by which imatinib ameliorates BO are incompletely understood. In the 
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rat BO model, imatinib inhibited the development of luminal occlusions without suppressing 
inflammatory cells, suggesting direct anti-fibrotic effects of imatinib (13). On the other hand, late 
administration of imatinib during the fibroproliferative phase of BO failed to prevent luminal 
obstruction (14). These findings suggest that imatinib exerts its preventative effects on fibroproliferative 
lesion development in tracheal allografts only when it is administered during the inflammatory phase 
of BO, and that the therapeutic target of imatinib may exist soon after tracheal transplantation.  
One of the cellular components that is involved in the fibroproliferative lesion is a bone marrow 
(BM)-derived mesenchymal progenitor cell, the fibrocyte. Fibrocytes represent 0.1–0.5% of the 
circulating leukocytes that differentiate from monocyte precursors and co-express the leukocyte marker 
CD45 and mesenchymal markers such as collagen I (15). Fibrocytes act as precursors of fibroblasts that 
participate in tissue remodeling and also the secretion of inflammatory cytokines, chemokines, and 
growth factors that contribute to the pathogenesis of fibrotic disorders (16-18). In lung tissue from BO 
patients who underwent lung transplantation, increased numbers of fibrocytes are identified in the 
alveolar parenchyma (19). The number of peripherally circulating fibrocytes was also increased with 
advancing BO stage, suggesting that fibrocytes may play an important profibrotic role in the 
development of BO (20).  
We hypothesized that in the BO model of HTT, imatinib ameliorated BO by inhibiting fibrocytes 
via unknown mechanisms. To test this hypothesis, we examined the causal role of fibrocytes in the 
development of BO by using GFP-chimeric mice. In this model, we evaluated the effect of imatinib on 
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the airway obstruction of transplanted tracheas as well as the effect on fibrocytes in vivo. Furthermore, 
to investigate the mechanisms underlying fibrocyte regulation by imatinib, we conducted an in vitro 
assessment of the targets of imatinib, i.e., c-Abl, c-Kit and PDGFR. 
 
METHODS 
Murine BO Model 
Animal studies were approved by the Institute for Experimental Animals, Kanazawa University 
Advanced Science Research Center. Male 7- to 10-week-old BALB/c, C57BL/6 wild-type mice, and 
GFP-positive transgenic (GFP-Tg) mice on a C57BL/6 background were purchased from Sankyo 
Laboratory Service Corporation (Toyama, Japan). The heterotopic tracheal transplantation (HTT) 
model was prepared as previously described (21, 22). A trachea from a BALB/c (isograft) or a C57BL/6 
(allograft) was transplanted into a BALB/c mouse. Imatinib was kindly provided by Novartis (Basal, 
Switzerland). This solution was diluted with 0.9% saline and injected intraperitoneally once daily (final 
dosage, 10 mg/kg/day). GFP-BM chimeras in which BM was replaced by GFP-marked BM cells were 
also prepared as previously described (23). The heterotopic tracheal transplantation was performed 2 
months after BM transplantation. Allogenic HTT was performed by transplanting tracheas from 
BALB/c to GFP-Tg, GFP-Tg to BALB/c and BALB/c to GFP-BM chimeras. Transplanted grafts were 
isolated on the indicated days after transplantation. Tracheal tissues were washed in phosphate-buffered 
saline (PBS), fixed in 10% formaldehyde and embedded in paraffin, or embedded directly in Tissue-
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Tek OCT compound (Sakura, Alphen aan den Rijn, The Netherlands) and snap-frozen in liquid nitrogen. 
Frozen tissues were serially cut into 14-μm thick cross-sections and stored at -80°C until used. 
 
Histopathological Analysis 
Tracheal graft sections were stained with hematoxylin and eosin. The degree of airway injury and 
luminal occlusion was examined as previously described (21). Evaluations used the NIH Image J 
program, version 1.49 p (National Institutes of Health. National Technical Information Service, 
Springfield, VA). 
 
Culturing Murine or Human Fibrocytes 
Human peripheral blood was collected from healthy adult volunteers after informed consent was 
obtained under the guidance of the ethical committee of Kanazawa University Graduate School of 
Medicine. Fibrocytes were harvested and cultured as previously described (24, 25). Briefly, peripheral 
blood mononuclear cells (PBMCs) were isolated from murine or human blood by using Lymphoprep™ 
(Progen Biotechnik). Human monocytes were isolated using a Dynabeads® FlowComp™ Human 
CD14 Kit (Life technologies). We prepared serum-free medium that consisted of RPMI 1640, 1% non-
essential amino acid, 1% pyruvate, 1% ITS-3, and 1% penicillin and streptomycin. We also prepared 
serum-containing medium consisting of DMEM, 10% heat-inactivated human AB serum (Sigma 
Aldrich), and penicillin/streptomycin. PBMCs or CD14-positive cells were cultured in 96-well plastic 
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plates or 8-well glass slides.  
 
Immunostaining 
Paraffin-embedded tissues were incubated with rabbit anti-GFP antibody in the experiments using GFP 
chimeric mice. Frozen tissues/cells were fixed in 4% paraformaldehyde, blocked with 2% skim milk in 
0.2% Triton X-100/PBS and were then stained with the primary antibodies. These sections were stained 
using specific antibodies followed by appropriate secondary antibodies and Hoechst 33342. The 
inflammatory cells observed in sections were expressed as the number of positively-staining cells per 
tracheal graft cross-section in 10 separate, high-power (✕400) fields. The densities of endothelial cells 
and pericytes were defined as the percent of pixels covered by each individual staining marker. The 
cellular localization of fluorescently labeled proteins was viewed under fluorescent microscopy (Zeiss). 
The details of the antibodies are provided in the online supplement. 
 
Phenotype, Migration and Differentiation of Fibrocytes 
We examined the protein expression of c-Abl, PDGFRα, PDGFRβ, and c-Kit by murine or human 
fibrocytes by using immunofluorescence or flow cytometry. Migration of fibrocytes was assessed by 
using Boyden chambers coated with collagen I, as previously described (26, 27). Recombinant human 
PDGF-AA, PDGF-BB, and SCF were used as the chemoattractants. Differentiation of fibrocytes was 
assessed as previously described (28). Imatinib or other inhibitors such as nilotinib (c-Abl inhibitor), 
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crenolanib (PDGFR inhibitor), or masatinib (c-Kit inhibitor) (Selleck Chemicals, Japan) were used at 
the appropriate concentrations. Additional details are provided in the online supplement. 
 
Transfection Experiment 
Human PBMCs were isolated and purified as described above. PBMCs were transfected with ABL1 
Silencer select siRNAs or control siRNAs (Applied Biosystems/Ambion, Austin, TX, USA) using 
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. After 5 days of culturing, 
the ratio of fibrocytes to total cells was determined by microscopic examination. 
 
Statistical Analysis 
Data are expressed as means ± SEM. Statistical analyses were performed using the Mann-Whitney U 
test. A P value less than 0.05 was considered to indicate statistical significance. All data were analyzed 




Imatinib attenuated luminal obstruction in the tracheal allograft 
In the BO model of HTT, the isografts showed epithelial injury soon after transplant, but recovery from 
injury was rapid and there was no evidence of luminal occlusion. On the other hand, the allografts 
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showed rapid development of severe epithelial injury that persisted. The lumens of the trachea gradually 
filled with fibroproliferative lesions leading to luminal occlusion by day 28 (Figure 1A and 1B).  
We next examined the effects of imatinib on the tracheal allografts, again using the HTT model. 
Recipients of allografts were treated daily with 10 mg/kg imatinib (prophylaxis) or a control (vehicle) 
from days 1 to 28 and were evaluated 28 days after transplantation. We also examined imatinib 
treatment administered to the allograft recipients from days 1 to 14 (early treatment) or from days 15 to 
28 (late treatment) (Figure 1C). The allografts of the recipients that were treated prophylactically with 
imatinib showed significantly reduced luminal occlusion in comparison with the allografts treated with 
vehicles (P < 0.05). However, early treatment as well as late treatment failed to inhibit the airway 
obstruction after 28 days (Figure 1D). Although prophylaxis showed significantly less luminal 
obliteration than that in late treatment, there were no statistically significant differences between 
prophylaxis and early treatment. These findings indicated that continuous administration of imatinib 
from the early post-transplant period was needed to effectively prevent BO. 
 
Bone marrow-derived progenitor cells contributed to BO 
To determine the origin of the fibroblasts in the BO model, we used GFP-Tg mice as recipients of the 
tracheal allografts or as donors of the tracheal grafts (Figure 2). When BALB/c tracheal grafts were 
ectopically transplanted into GFP-Tg mice, the cells that accumulated in the obliterative lesions at 28 
days were GFP-positive (Figure 2A). On the other hand, when GFP-Tg-derived grafts were transplanted 
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into BALB/c mice, the cells that accumulated in the obliterative lesion were GFP-negative (Figure 2B), 
indicating that the migrated cells that caused tracheal stenosis were of recipient origin. To determine to 
what extent BM–derived recipient cells contributed to the occlusion of the allograft, we used GFP-
chimeric mice in which the original BM was replaced by GFP-marked BM cells. When BALB/c 
tracheal grafts were transplanted into GFP-chimeric mice, 75.4 ± 5.7% of the cells in the obliterative 
area were GFP–positive (Figure 2C). The GFP–positive cells included round cells and spindle-shaped 
cells. The round cells were positive for CD45 (Figure 2D), indicating that they were inflammatory cells, 
such as macrophages and lymphocytes. The spindle-shaped cells were positive for collagen I (Figure 
2E), indicating that they were mesenchymal cells, fibrocytes. These findings suggested that BM-derived 
fibrocytes contributed to the luminal obstruction in the BO model.  
 
Imatinib reduced the number of fibrocytes in vivo 
To clarify the effect of imatinib on fibrocytes in vivo, we determined the number of fibrocytes 
(CD45+/Pro-collagen I+) in each transplanted graft using immunofluorescent staining (Figure 3A). In 
all three groups, the number of infiltrating fibrocytes in the tracheal grafts gradually increased with time, 
peaked at day 7 and decreased thereafter. In the allografts obtained on days 3 and 7, the number of 
fibrocytes in the tracheal allograft of vehicle-treated recipients was significantly higher than those of 
the isograft. Imatinib administration significantly reduced the number of fibrocytes compared with 
vehicle (Figure 3B). 
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We next examined the three groups to determine the effect of imatinib on the accumulation of 
inflammatory cells in the transplanted graft after 7 days (Figure 3C). The numbers of inflammatory 
cells were all elevated in the tracheal allograft compared with those of the isograft. Unlike the number 
of fibrocytes, there were no significant differences in these inflammatory cell numbers between vehicle- 
and imatinib-treated allografts. Likewise, imatinib treatment did not affect the number of PECAM-1+ 
endothelial cells or NG2+ pericytes. 
We examined murine fibrocytes for their expression of target proteins of imatinib. After 5 days of 
culturing murine PBMCs, we obtained spindle-shaped cells (fibrocytes) that co-expressed CD45 and 
procollagen I. Fibrocytes expressed high levels of c-Abl and PDGFRβ and low levels of c-Kit. These 
data indicated that c-Abl and PDGFRβ may be molecular targets for imatinib treatment (Figure 4). 
 
Imatinib inhibited fibrocyte migration and differentiation in vitro 
Fibrocytes originate from CD14+ circulating blood mononuclear cells (a subpopulation of monocytes) 
(15, 29, 30). After 7 days of culturing human CD14+ monocytes in serum-containing medium, we 
observed spindle-shaped cells, namely, fibrocytes; over 85% of the cells were double positive for CD45 
and collagen I (Figure 5A). We first examined the expression of target proteins of imatinib on the surface 
of human CD14+ monocytes and fibrocytes. Monocytes were positive for c-Abl and c-Kit, but negative 
for PDGFR (Figure 5B). This phenotype of monocytes was distinctly different from that of fibrocytes 
that were positive for c-Abl, PDGFR-β, and c-Kit, but negative for PDGFR-α. 
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We assessed the effects of different cytokines on the migration of fibrocytes using Boyden 
chambers. PDGF-BB induced strong migration, whereas PDGF-AA and SCF did not (Figure 5C). 
PDGF-BB-induced migration of fibrocytes was significantly inhibited by imatinib treatment in a dose-
dependent manner (Figure 5D), indicating that imatinib suppressed fibrocyte migration via the PDGF-
PDGFRβ axis. 
To analyze the effect of imatinib on the differentiation of fibrocytes, PBMCs were cultured in 
serum-free medium. After 5 days of culture, we observed the appearance of spindle-shaped cells, 
fibrocytes (Figure 6). Imatinib treatment reduced fibrocytes on day 5 in a dose-dependent manner, 
indicating that imatinib inhibited the differentiation of fibrocytes from CD14+ monocytes (Figure 6A, 
B). Among other tyrosine kinase inhibitors including nilotinib, crenolanib, and masitinib, only nilotinib 
significantly inhibited differentiation of fibrocytes compared with controls (Figure 6C, D, E). Since 
nilotinib is more potent than imatinib in inhibiting activity of c-Abl tyrosine kinase (31, 32), c-Abl 
activity may be a possible candidate for regulating the differentiation into fibrocytes. 
Finally, we used siRNA for c-Abl to determine if c-Abl could affect fibrocyte differentiation from 
CD14+ monocytes. PBMCs that were transfected with 25 nM or 50 nM siRNA showed significantly 
less differentiation of fibrocytes compared with non-specific siRNA-transfected controls (Figure 6F, G). 
These findings indicated that imatinib might inhibit fibrocyte induction from CD14+ monocytes via 





Our study demonstrated that most of the accumulated mesenchymal cells in the tracheal allograft were 
of BM origin, and that imatinib ameliorated luminal occlusion by reducing the number of fibrocytes in 
the murine BO model. Moreover, imatinib inhibited fibrocyte migration as well as the differentiation of 
CD14+ monocytes into fibrocytes in vitro, likely via the specific inhibition of c-Abl signaling. 
Fibroblasts are generated from a variety of cell sources including resident mesenchymal cells, 
epithelial and endothelial cells, as well as BM-derived progenitor cells called fibrocytes (33-37). 
Mesenchymal stem cells are also associated with the pathogenesis of BO (38). It remains to be 
determined which cell sources are associated with the fibrogenesis of BO. Using a rat model, Sato et al. 
demonstrated that myofibroblasts in lung allografts were of extrapulmonary origin (39). However, the 
study did not determine whether the fibroblasts were derived from BM cell fibrocytes or surrounding 
mesenchymal cells. To address this issue, we established GFP chimeric mice to identify the origin of 
fibroblast-like cells. Our study indicated that fibrocytes participate in the fibrogenesis of BO in the HTT 
model. 
The HTT model consists of an airway injury phase (days 1-3), an early inflammatory phase (days 
3-14) and a late fibroproliferative phase (days 14-28). The mechanism responsible for the anti-fibrotic 
effect of imatinib was thought to be the inhibition of the early inflammatory phase because late 
administration of imatinib failed to exert anti-fibrotic effects. Moreover, imatinib administration 
reduced the fibrocyte counts in the tracheal allograft in the early inflammatory phase of the HTT model. 
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Based on our results, although the differences between the mouse model and human disease should be 
considered, prophylactic administration of imatinib is recommended for the treatment of BO. 
Our study demonstrated for the first time that imatinib inhibited the differentiation of fibrocytes 
from CD14+ monocytes by inhibiting c-Abl tyrosine kinase signaling. c-Abl is a non-receptor tyrosine 
kinase protein that regulates cellular proliferation and cytoskeletal remodeling (40). c-Abl is also 
involved in the differentiation of diverse cell types, including adipocytes, osteoblasts, and dendritic cells 
(41-43). The results of our study suggest that c-Abl tyrosine kinase signaling may play an important 
role in the differentiation of CD14+ monocytes into fibrocytes.  
Imatinib inhibits both migration and differentiation of fibrocytes in vitro; however, it is unknown 
which occurs predominantly in vivo. Previous animal studies suggest that differentiation of fibrocytes 
from circulating monocytes mainly occurs at tissue sites and not in the peripheral blood (17, 44, 45). A 
recent study demonstrated that the monocyte-macrophage axis contributed to the development of 
chronic graft-versus-host disease, including BO (46). In our HTT model, a larger number of monocytes 
accumulated in the tracheal allograft than the isograft, which may trigger graft rejection (47, 48). 
Therefore, imatinib may have mainly inhibited the differentiation of fibrocytes from monocytes in the 
transplanted graft rather than inhibiting the migration of circulating fibrocytes. 
There are several limitations in our study. The murine trachea is anatomically different from the 
bronchiole in humans. In addition, neither hemoperfusion nor ventilation occurs in this HTT model. 
Finally, the tracheal obstruction in this model develops within one month compared with years in 
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transplanted human lungs (49). Although there are other BO models including an orthotopic tracheal or 
lung transplant system, these models are technically more challenging and represent a relatively earlier 
stage of bronchiolitis than the HTT model (49). Because the HTT model mimics the allo-immune 
pathological process of BO, it is useful for evaluating the pathogenetic role of fibrocytes in the 
development of BO.  
In conclusion, imatinib could be potentially useful in preventing BO in lung transplant recipients. 
Our study also provides evidence that imatinib impairs fibrocyte differentiation by inhibiting c-Abl 
signaling in vitro. Another possible treatment of choice may be nilotinib, which has more potent and 
selective effects on c-Abl than imatinib and may therefore exert more beneficial effects on the 
suppression of BO. Further understanding of the potential roles of fibrocytes in the development of BO 
may help to develop effective biomarkers and novel anti-fibrotic therapy.  
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Figure 1. Morphological features of murine bronchiolitis obliterans (BO) after heterotopic tracheal 
transplantation. (A) Representative images of hematoxylin and eosin (H&E) staining of tracheal isograft 
and allograft tissue on days 7, 14, and 28. Insets in each image show a high power field of airway lesion. 
Scale bar = 100 μm. (B) Quantitative morphometric analysis of airway injury and luminal occlusion in 
isograft and allograft. Data represent the means ± SEM. n = 6 - 8/group. *, P < 0.05 for allograft 
compared with isograft. (C) Representative H&E stained sections of vehicle-treated tracheal allograft 
(Vehicle), imatinib-treated tracheal allograft on days 1 through 28 (Prophylaxis), on days 1 through 14 
(Early treatment), and on days 15 through 28 (Late treatment) after transplantation. Scale bar = 100 μm. 
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(D) Quantitative morphometric analysis of airway injury and luminal occlusion in each group. Data 
represent the means ± SEM. n = 6 - 8/group. *, P < 0.05. 
 
Figure 2. Immunohistochemical staining of Green fluorescent protein (GFP) in allograft tissue sections 
28 days after transplantation. (A-C) Representative images of GFP immunohistochemical stains in 
BALB/c tracheas transplanted to GFP-transgenic mice (A), GFP-transgenic mouse tracheas 
transplanted to BALB/c mice (B), and BALB/c tracheas transplanted to C57BL/6 wild-type mice treated 
with GFP-transgenic BM transplantation (C). High power field of obliterative area is shown enlarged 
below each image. Brown stain indicates GFP-positive cells. All sections are counterstained lightly with 
hematoxylin to visualize negatively stained cells. Scale bars = 50 μm. (D and E) Representative images 
of immunofluorescent staining of BALB/c tracheas transplanted to C57BL/6 wild-type mice treated 
with GFP-transgenic BM transplantation. GFP-positive cells (green) are also positive for CD45 (red) 
(D) and collagen-I (red) (E). Scale bar = 20 μm. 
 
Figure 3. Fibrocytes, inflammatory cells and vessel markers in transplanted tracheal grafts. (A) 
Representative image of immunofluorescence staining with anti-CD45 (green), anti-pro-collagen I (red) 
antibodies, and Hoechst 33342 (blue) in vehicle- and imatinib-treated allograft. Double-positive cells 
expressing CD45 and pro-collagen I are fibrocytes (arrows). Scale bar = 20 μm. (B) Time course 
showing the number of fibrocytes in an isograft, and vehicle- and imatinib-treated allografts. Data 
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represent the means ± SEM. n = 4/group. *, P < 0.05 for vehicle-treated allograft compared with isograft. 
**, P < 0.05 for imatinib-treated compared with vehicle-treated allograft. (C) Inflammatory cells 
included monocytes (CD11b), macrophages (F4/80), T lymphocytes (CD3) and neutrophils (MPO). 
Vessel markers included endothelial cells (PECAM-1) and pericytes (NG2). Data represent the means 
± SEM. n = 4/group. *, P < 0.05. NS = not significant; Vehicle = vehicle-treated allograft; Imatinib = 
imatinib-treated allograft.  
 
Figure 4. Protein expression in murine fibrocytes. (A) Representative images of cells immunostained 
for pro-collagen I (red), CD45 (green) and Hoechst 33342 (blue) in cultured murine fibrocytes. (B) 
Representative images showing cells immunostained for c-Abl, PDGFRα, PDGFRβ, and c-Kit (red). 
Scale bar = 20 μm.  
 
Figure 5. Protein expression by human fibrocytes and their migration. (A) Representative image of 
fibrocytes after 8 days of cultivation of human blood monocytes. Scale bar = 100 µm. Fibrocytes were 
over 90% pure as determined by flow cytometric analysis using anti-CD45 and anti-collagen I 
antibodies. (B) Protein expression by human monocytes and fibrocytes assessed by flow cytometry. The 
analyzed proteins included CD14 (monocyte marker), collagen I (mesenchymal marker), c-Abl, 
PDGFR-α, PDGFR-β, and c-Kit. Representative experiments are shown in red, with isotype controls 
shown in gray shades. (C) Effect of chemotactic factors on fibrocyte migration assessed by using 
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Boyden-chamber assays. The cells that migrated to the lower side of the membrane were counted and 
expressed as a percentage of total cells. The data represent means ± SEM of 3 independent experiments. 
*, P < 0.05. (D) Effect of imatinib on PDGF-BB-enhanced migration of fibrocytes. The data represents 
means ± SEM of 3 independent experiments. *, P < 0.05.  
 
Figure 6. Imatinib inhibited fibrocyte differentiation. (A) Representative image of cultured fibrocytes. 
Peripheral blood mononuclear cells (PBMCs) were cultured in serum-free medium for 5 days in the 
presence or absence of imatinib. Some PBMCs became spindle-shaped fibrocytes (arrow). Scale bar = 
100 µm. (B) The number of fibrocytes was assessed after 5 days of culture and expressed as a percentage 
of total cells. (C-E) PBMCs treated with other inhibitors including nilotinib, crenolanib, and masitinib. 
The number of fibrocytes was evaluated after 5 days of culture. The data represent means ± SEM of 3 
independent experiments. (F) Knockdown of c-Abl inhibited the differentiation of fibrocytes 48 h after 
incubation. Flow cytometric analysis of c-Abl protein in cultured-fibrocytes after siRNA transfection. 
Black-filled histograms show the cultured-fibrocytes in the presence of 50 nM c-Abl siRNA, gray-
shaded histograms show results from treatment with control siRNA, and white histograms show isotype 
control (G) The siRNA knockdown of c-Abl significantly decreased the number of fibrocytes compared 
with siRNA-free controls. The data represent mean ± SEM of 3 independent experiments. *, P < 0.05. 
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